1 / 50

Serous Epithelial Ovarian Cancers: A Pathologic and Clinical Perspective

Serous Epithelial Ovarian Cancers: A Pathologic and Clinical Perspective. Amanda Nickles Fader, MD Associate Professor, The Kelly Gynecologic Oncology Service Johns Hopkins Medicine. Disclosures. I have no financial relationships to disclose. My First Patient: Erin. Optimal Debulk to R0

wdiane
Télécharger la présentation

Serous Epithelial Ovarian Cancers: A Pathologic and Clinical Perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Serous Epithelial Ovarian Cancers: A Pathologic and Clinical Perspective Amanda Nickles Fader, MD Associate Professor, The Kelly Gynecologic Oncology Service Johns Hopkins Medicine

  2. Disclosures • I have no financial relationships to disclose

  3. My First Patient: Erin Optimal Debulk to R0 Stage III low-grade serous carcinoma A crazy chemo regimen that included carbo/doxil/avastin NED x 76 months

  4. Objectives • To review the epidemiology, molecular biology and clinical behavior of low-grade (LGSC) compared with high-grade serous carcinoma of the ovary (HGSC) • To review the clinical trials facilitated from the rare tumor networks • To understand the evidence supporting best surgical, chemotherapeutic and hormonal practices for LGSC vs HGSC

  5. One Size Doesn’t Fit All • Most medical treatments are designed for the “average patient ” as “one-size-fits-all-approach,” that is successful for some patients but not for others • Precision medicine: an innovative approach to disease prevention and treatment that takes into account differences in people’s genes, environments and lifestyles • Pioneering studies in GYN Oncology with an emphasis on rare tumors • United States President Obama’s Precision Medicine Initiative

  6. Background • Epithelial ovarian cancer (EOC) is not one, but several, distinct entities • Yet in last decade, most women with EOC have been treated identically • Advances in the understanding of heterogeneity of ovarian malignancies • Refining pathologic diagnostic criteria • Molecular biology and genetics Jemal, Cancer Stats. 2014

  7. Background • Serous carcinomas: 65% of all epithelial ovarian cancers • Histologic grade an important determinant of survival Malpica et al, Am J Pathol 2007; Vang et al, Am J Surg Path, 2008

  8. Two-tiered Histologic Criteria LGSC HGSC Malpica et al, Am J Path, 2007

  9. High-grade serous carcinoma mimicking serous borderline tumor at low-power

  10. High-grade serous carcinoma with high-grade cytology and mitotic activity

  11. Typical Serous Borderline Tumor

  12. Clear cell CA mimicking Micropapillary Serous Borderline Tumor

  13. Micropapillary Serous Borderline Tumor

  14. Ancillary Analysis: GOG 158 • Retrospectively reviewed data of 290 patients with stage III serous carcinoma of the ovary treated with upfront surgery + T/C chemo • Panel of 6 GYN pathologists performed a blinded review to reclassify these tumors using the binary grading system • With binary system, patients with LGSC had significantly longer PFS than those with HGSC • Multivariate analysis: no difference in outcome in patients with grade 2 or 3 tumors using FIGO system Bodurka et al, Cancer, 2011

  15. Hormonal Receptors • LGSC 3x more likely to robustly express estrogen and progesterone receptors than HGSC

  16. Map Kinase Pathway

  17. Mutations of LGSC • LGSC driven by activating mutations of: • PIK3CA (40%) • Inactivating mutations of PTEN (3-8%) • Expression of insulin-like growth factor (IGF) receptor • PIK3CA mutations, like PTEN loss, lead to constitutive activation of PI3K signaling • Downstream effectors of IGF pathway, including PI3K/AKT/mTOR have well-established roles as mitogens in carcinogenesis

  18. Segregation of LGSC vs. HGSC in Genomic Profiling Studies Bonome et al, Cancer Res. 2005

  19. Epidemiology • LGSC accounts for 10% of all serous ovarian carcinomas • 3-5% of all epithelial ovarian cancers • Serous borderline tumor--a precursor lesion to LGSC, which likely originates in the ovary • Deleterious BRCA1 and 2 mutations infrequently observed with LGSC, but observed in as high as 18-47% of women diagnosed with HGSC Gershenson et al, Gynecol Oncol, 2012 Fader et al, Obstet Gynecol, 2013

  20. Epidemiology • Women w/ LGSC diagnosed at a younger age and have a longer overall survival than those with HGSC • Pooled retrospective data on 5-year survival • 40-56% for advanced LGSC versus 9-34% for HGSC • LGSC have lower response rates to conventional chemotherapy and overall poor survival outcomes

  21. Surgery is the mainstay of therapy.

  22. Survival by Residual Disease After Primary Cytoreductive Surgery: GOG 182 • An ancillary analysis of women with stage III-IV epithelial ovarian cancer • Treated with primary cytoreductive surgery • T/C compared with triplet or sequential doublet regimens • 189 had Grade 1 disease (surrogate for LGSC) • On multivariate analysis, only residual disease status after primary debulking was significantly associated with survival (p=.006) Fader et al, Obstet Gynecol, 2013

  23. Survival by Residual Disease After Primary Cytoreductive Surgery: GOG 182 *Grade 1 serous used as a surrogate For LGSC N=187 patients P<.001 Fader et al, Obstet Gynecol, 2013

  24. Survival by Residual Disease After Primary Cytoreductive Surgery: GOG 182 *Grade 1 serous used as a surrogate For LGSC N=187 patients P<.001 Fader et al, Obstet Gynecol, 2013

  25. Role of 2ndary Cytoreduction 41 pts; Median time between primary tumor debulking and SCRS was 33.2 months 32 (78%) had gross residual disease at the completion of secondary surgery The median PFS w/ NGRD after SCRS was 60.3 months, compared to 10.7 months for patients with gross residual disease (p = 0.008) Median OS w/ NGRD after SCRS was 167.5 months compared to 88.9 months (p = 0.10) Crane et al, Gynecol Oncol, 2015

  26. Neoadjuvant chemotherapy? • Relative chemoresistance also observed in a review of women who received neoadjuvant chemotherapy for advanced stage LGSC • 25 patients, median age 45 years • Only 4% response rate • Half of evaluable patients had a greater than 50% reduction in serum CA 125 levels after chemo--only one patient had an objective response by imaging assessment Schmeler et al, Gynecol Oncol. 2008

  27. CA-125? • Are standard parameters for evaluation of response—serial imaging and CA 125—adequate determinants of outcome? • What is the prognostic significance of serum CA-125 levels in women with LGSC?

  28. CA-125 Response Rates in Grade 1 Serous Carcinoma • Ancillary analysis of GOG 182 • 184 had grade 1 serous disease and CA-125 levels Fader et al, Gynecol Oncol. 2013

  29. CA-125 Normalization During Chemo and Survival Fader et al, Gynecol Oncol. 2013

  30. Chemotherapy After Primary Cytoreductive Surgery? • Evidence to date suggests that LGSC relatively resistant to first-line chemotherapy • MD Anderson: Review of 112 patients with newly diagnosed stage II-IV LGSC treated with primary surgery and platinum-based chemotherapy • Median age 43 • Treatment not as successful as expected given high frequency of persistent disease at completion of therapy and low negative second-look rate • Only 52% of patients were disease-free after PCS and completion of platinum-based chemo Gershenson et al, Gynecol Oncol. 2008

  31. MD Anderson Experience • Stage I –IV LGSC and Stage II-IV LGSPC • 350 eligible patients • Median PFS 28.1 months • Median OS 101.7 months • MV analysis: compared w/ women age ≤35 years, those diagnosed at age >35 years had a 43% reduction in likelihood of dying (hazard ratio, 0.53; 95% CI, 0.37 to 0.74; P < .001) Gershenson et al, JCO, 2015

  32. MD Anderson Experience: The Impact of Residual Disease • Having disease present at completion of primary therapy was associated with a 1.78 increased hazard of dying compared with being clinically disease free (P < .001) Gershenson et al, JCO, 2015

  33. MD Anderson Experience • Similar trends noted in the smaller patient LGSPC cohort • Women with LGSPC had a 41% decreased chance of dying (hazard ratio, 0.59; 95% CI, 0.36 to 0.98; P = .04) compared with those with LGSOC Gershenson et al, JCO, 2015

  34. So… • Is chemotherapy beneficial in the treatment of low grade serous carcinoma of the ovary? • Well…it depends

  35. Chemotherapy for Recurrence: Appraisal Farley et al, Lancet Oncol. 2013; Gershenson et al, Gynecol Oncol. 2012; Gershenson, et al Gynecol Oncol. 2009

  36. Evolution of Clinical Trials in LGSC • Development of the binary grading system for serous carcinomaand establishment of the GOG Rare Tumor Committee in 2005 • Led to recognition of this histologic subtype • Dawn of separate clinical trials for women diagnosed with this rare malignancy • Principle of separate clinical trials for major rare histologic subtypes of ovarian cancer subsequently validated in two consensus confereneces • Clear cell carcinoma, mucinous carcinoma, and LGSC Stuart GCE, In J Gynecol Oncol, 2011

  37. MEK Inhibition: GOG 239 • Primary objectives: • Determine response rate of patients and toxicity of selumetinib • Secondary objectives: • Estimate PFS and OS • Translational research objectives: • BRAF and KRAS mutation analysis and relationship with tumor response Farley et al, Lancet Oncol. 2013

  38. GOG 239 • Selumetinib: potent, selective, orally-available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein (MAP) kinase kinase, MEK-1/2 • Open label Phase II study • Eligibility • Women with recurrent low-grade serous (invasive micropapillary) carcinoma of ovary or peritoneum • Biopsy proven • Prospective pathologic evaluation • Treatment: selumetinib 50 mg BID (4 wks = 1 cycle) Farley et al, Lancet Oncol. 2013

  39. N=52 patients Farley et al, Lancet Oncol. 2013

  40. Survival Outcomes: GOG 239 Farley et al, Lancet Oncol. 2013

  41. Mutational Analysis of LGSC Tumors • 65% of tumors found to have a mutation in one of 114 oncogenes • 62% specimens with mutations in RAS genes • 6% specimens with mutations in BRAF gene • Newly identified mutations in N and H ras genes Farley et al, Lancet Oncol. 2013

  42. Extraordinary Responders:LGSC • Next-gen sequencing was used to analyze a pt >5 yr PFS patient's tumor as well as an additional 28 SB/LGS tumors • Analysis of extraordinary responder's tumor identified a 15-nucleotide deletion in negative regulatory helix of the MAP2K1 gene encoding for MEK1 • Retained sensitivity to selumetinib • Additional mutations predicted to induce extracellular signal-regulated kinase pathway activation in 82% (23 of 28), including two patients with BRAF fusions Grisham et al, JCO, 2015

  43. The Johns Hopkins Experience • Since 2011, have treated women with advanced LGSC after primary cytoreductive surgery with hormonal therapy alone • Aromatase inhibition • Continue indefinitely until disease progression or toxicity

  44. Patient 1 • 38 year old w/ Stage IV LGSC—extensive parenchymal liver metastases and carcinomatosis • Carbo/Taxol x2—disease progression and SBO • Debulk with total colectomy, diaphragm, spleen, ileostomy—July 1, 2014 • Optimal <1 cm residual but tiny parenchymal liver mets could not be debulked

  45. Patient 1 • Tumor • ER +90% • PR +40% • AI initiated—CT @ 6 months w/ regression of all liver mets • Asymptomatic w/ tiny, stable liver mets x 18 months

  46. Future Directions: LGSC Trials • Whether high rate of stable disease observed in studies of both primary and recurrent LGSC relates more to tumor biology and cytoreductive effort or the influence of chemotherapy remains unclear • Biomarker-driven clinical trials will increase opportunities to refine existing treatments and may optimize survival outcomes for women with LGSC

  47. Future Directions: LGSC Trials • Ancillary analysis of GOG IP trials and impact of IP chemo on low-grade, type I epithelial subtypes • Neoadjuvant MEK +/- AKT study in advanced LGSC—NRG vs. institutional

  48. Trials Under Development: GOG/NRG RTC Randomized Phase II (Fader/Gershenson) Primary ovarian, fallopian tube or PPC LGSC Attempt at maximal surgical cytoreduction Carboplatin/paclitaxel x 6 cycles Trametinib and AKT inhibitor x6 cycles f/b maintenance

  49. Conclusions • Development of binary (two-tiered) grading system for serous carcinoma of the ovary has facilitated the concept of separate clinical trials for this rare subtype • Low-grade serous carcinoma associated with • 20%-40% frequency of KRAS mutations, a 5% frequency of BRAF mutations, and a high rate of ER and PR positivity • PI3K and IGF pathway significant- • Potential for MTOR and AKT inhibition

  50. Thank You! • Dr Vang • Our patients

More Related